Compare DMRA & DMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DMRA | DMC |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | Cayman Islands |
| Employees | 7 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | N/A |
| Metric | DMRA | DMC |
|---|---|---|
| Price | $33.42 | $28.36 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $43.00 | N/A |
| AVG Volume (30 Days) | ★ 864.6K | 337.1K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.50 | $27.51 |
| 52 Week High | $34.89 | $30.17 |
| Indicator | DMRA | DMC |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 53.26 |
| Support Level | $22.71 | $27.51 |
| Resistance Level | N/A | $29.28 |
| Average True Range (ATR) | 2.81 | 0.82 |
| MACD | 0.44 | 0.06 |
| Stochastic Oscillator | 84.06 | 31.26 |
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.